{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:28:03Z","timestamp":1793395683633,"version":"4.5.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Currently, there are limited treatment options available that effectively treat FM symptoms. Psilocybin-assisted therapy (PAT) is an emerging combined drug-therapy intervention, but no studies to-date have investigated PAT for FM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, we report findings from an open-label, pilot clinical trial of PAT for FM (<jats:italic>N<\/jats:italic>\u2009=\u20095). In conjunction with psychotherapy (two preparatory, four integration sessions), participants received two doses of oral psilocybin (15\u2005mg and 25\u2005mg) delivered two weeks apart.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Regarding safety (primary outcome), there were transient elevations of blood pressure or heart rate during dosing which normalized by the end of treatment, with no serious adverse events. Four of five participants reported transient headaches following dosing. Compared to baseline, participants reported clinically meaningful improvements in the following secondary outcomes one month following their second psilocybin dose (reported as Cohen's <jats:italic>d<\/jats:italic>): pain severity [<jats:italic>d<\/jats:italic>\u2009=\u2009\u22122.1, 95% CI(\u22123.7 to \u22120.49)], pain interference [<jats:italic>d<\/jats:italic>\u2009=\u2009\u22121.8, 95% CI (\u22123.27 to \u22120.24)], and sleep disturbance [<jats:italic>d<\/jats:italic>\u2009=\u2009\u22122.5, 95% CI (\u22124.21 to \u22120.75)]. Using the Patient Global Impression of Change, one participant reported their symptoms \u201cvery much improved,\u201d two reported \u201cmuch improved,\u201d and two reported \u201cminimally improved.\u201d We stopped recruitment early because of concerns about generalizability and changes in FDA guidance for psychedelic clinical trials that occurred data collection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This small open-label trial preliminarily supports that PAT is well-tolerated by people with FM, establishing a basis for larger randomized controlled trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri>, identifier, (NCT05128162).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpain.2025.1527783","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:04:01Z","timestamp":1742281441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial"],"prefix":"10.3389","volume":"6","author":[{"given":"Jacob S.","family":"Aday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Hosanagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Tarnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Weston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamarie","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Harte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Pouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas G.","family":"Glynos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Guss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Mashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Clauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152060","DOI":"10.1016\/j.semarthrit.2022.152060","article-title":"The economic burden of fibromyalgia: a systematic literature review","volume":"56","author":"D'Onghia","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41582-024-00966-8","article-title":"Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms","volume":"20","author":"Kaplan","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia: a clinical review","volume":"311","author":"Clauw","year":"2014","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e12137","DOI":"10.1111\/jabr.12137","article-title":"The neurobiology of central sensitization","volume":"23","author":"Harte","year":"2018","journal-title":"J Appl Biobehav Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.rdc.2009.05.003","article-title":"Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine","volume":"35","author":"Hassett","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamainternmed.2020.5651","article-title":"Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis","volume":"181","author":"Mascarenhas","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1124\/jpet.115.227298","article-title":"Fibromyalgia syndrome in need of effective treatments","volume":"355","author":"Theoharides","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1320780","DOI":"10.3389\/fpsyt.2024.1320780","article-title":"Study protocol for \u201cpsilocybin in patients with fibromyalgia: brain biomarkers of action\u201d","volume":"15","author":"Bornemann","year":"2024","journal-title":"Front Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: a systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"711255","DOI":"10.3389\/fphar.2021.711255","article-title":"Role of the 5-HT2A receptor in acute effects of LSD on empathy and circulating oxytocin","volume":"12","author":"Holze","year":"2021","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression","volume":"34","author":"Mertens","year":"2020","journal-title":"J Psychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jcbs.2020.01.005","article-title":"Psychedelics and psychological flexibility \u2013 results of a prospective web-survey using the acceptance and action questionnaire II","volume":"16","author":"Close","year":"2020","journal-title":"J Contextual Behav Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-01158-w","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder","volume":"11","author":"Doss","year":"2021","journal-title":"Transl Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s41465-019-00151-6","article-title":"Can psychedelic drugs attenuate age-related changes in cognition and affect?","volume":"4","author":"Aday","year":"2019","journal-title":"J Cogn Enhanc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of Major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on Major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"key":"B23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"269881119897615","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol (Oxf)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1177\/0269881116675764","article-title":"Psilocybin and palliative end-of-life care","volume":"30","author":"Shelton","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","article-title":"Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)","volume":"24","author":"Ramachandran","year":"2018","journal-title":"Neurocase"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/head.14656","article-title":"CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity","volume":"64","author":"Madsen","year":"2024","journal-title":"Headache"},{"key":"B32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"R1282","DOI":"10.1016\/j.cub.2023.10.016","article-title":"Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain","volume":"33","author":"Kolbman","year":"2023","journal-title":"Curr Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2049463722111496","article-title":"Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey","volume":"16","author":"Bonnelle","year":"2022","journal-title":"Br J Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"735427","DOI":"10.3389\/fpsyt.2021.735427","article-title":"Self-medication for chronic pain using classic psychedelics: a qualitative investigation to inform future research","volume":"12","author":"Bornemann","year":"2021","journal-title":"Front Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"109528","DOI":"10.1016\/j.neuropharm.2023.109528","article-title":"Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs","volume":"233","author":"Zia","year":"2023","journal-title":"Neuropharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2021.2022817","article-title":"Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia","author":"Glynos","year":"2022","journal-title":"J Psychoact Drugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","article-title":"The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review","volume":"32","author":"Kroenke","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.31234\/osf.io\/u6v9y","volume-title":"The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)","author":"Guss","year":"2020"},{"key":"B42","first-page":"1517","article-title":"Psychedelic-assisted psychotherapy: where is the psychotherapy research?","volume-title":"Psychopharmacology","author":"Aday","year":"2024"},{"key":"B43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"02698811221131994","DOI":"10.1177\/02698811221131994","article-title":"Body mass index (BMI) does not predict responses to psilocybin","volume":"37","author":"Spriggs","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"0269881121991822","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","article-title":"PROMIS\u00ae-29 v2.0 profile physical and mental health summary scores","volume":"27","author":"Hays","year":"2018","journal-title":"Qual Life Res"},{"key":"B47","article-title":"Obtain & Administer Measures: healthmeasures.net","year":"2024"},{"key":"B48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pain.2009.12.016","article-title":"Validation of the chronic pain acceptance questionnaire (CPAQ) in an internet sample and development and preliminary validation of the CPAQ-8","volume":"149","author":"Fish","year":"2010","journal-title":"Pain"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"B50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"B51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B54","article-title":"Psychedelic Drugs: Considerations for Clinical Investigations","year":"2023"},{"key":"B55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B56","article-title":"Meaningful Change for PROMIS\u00ae. healthmeasures.net","year":""},{"key":"B57","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/j.pain.0000000000001121","article-title":"Estimating minimally important differences for the PROMIS pain interference scales: results from 3 randomized clinical trials","volume":"159","author":"Chen","year":"2018","journal-title":"Pain"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","article-title":"Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures","volume":"30","author":"Terwee","year":"2021","journal-title":"Qual Life Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: a case series","volume":"164","author":"Lyes","year":"2022","journal-title":"Pain"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-017-0186-6","article-title":"Psychoactive substances as a last resort\u2014a qualitative study of self-treatment of migraine and cluster headaches","volume":"14","author":"Andersson","year":"2017","journal-title":"Harm Reduct J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"B62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2024.99","article-title":"LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up","volume":"225","author":"Holze","year":"2024","journal-title":"Br J Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0279073","DOI":"10.1371\/journal.pone.0279073","article-title":"\u201cA sense of the bigger picture:\u201d A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use","volume":"17","author":"DellaCrosse","year":"2022","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/02698811211055809","article-title":"Debunking the myth of \u2018blue mondays\u2019: no evidence of affect drop after taking clinical MDMA","volume":"36","author":"Sessa","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/revneuro-2020-0094","article-title":"Psychedelic drugs and perception: a narrative review of the first era of research","volume":"32","author":"Aday","year":"2021","journal-title":"Rev Neurosci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"00221678241230609","DOI":"10.1177\/00221678241230609","article-title":"Increases in aesthetic experience following ayahuasca use: a prospective, naturalistic study","author":"Aday","year":"2024","journal-title":"J Humanist Psychol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.26.24311611","article-title":"The phenomenology of psilocybin\u2019s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting","author":"Klu\u010dkov\u00e1","year":"2024","journal-title":"medRxiv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/10481885.2022.2106139","article-title":"Psychedelic psychoanalysis: transformations of the self","volume":"32","author":"Rundel","year":"2022","journal-title":"Psychoanal Dialogues"},{"key":"B70","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1037\/scp0000242","article-title":"Spiritual experiences in psychedelic-assisted psychotherapy: case reports of communion with the divine, the departed, and saints in research using psilocybin for the treatment of alcohol dependence","volume":"8","author":"Podrebarac","year":"2021","journal-title":"Spiritual Clin Pract"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2024.2312980","article-title":"Effects of ayahuasca on gratitude and relationships with nature: a prospective, naturalistic study","author":"Aday","year":"2024","journal-title":"J Psychoact Drugs"},{"key":"B72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamapsychiatry.2023.0549","article-title":"Emerging challenges for psychedelic therapy","volume":"80","author":"Aday","year":"2023","journal-title":"JAMA Psychiatry"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2025.1527783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:04:07Z","timestamp":1742281447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2025.1527783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":74,"alternative-id":["10.3389\/fpain.2025.1527783"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2025.1527783","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"article-number":"1527783"}}